Informatie:
Fout:
ID
34371
Beschrijving
Firmagon (Degarelix) Intermittent Therapy; ODM derived from: https://clinicaltrials.gov/show/NCT01512472
Link
https://clinicaltrials.gov/show/NCT01512472
Trefwoorden
Versies (1)
- 16-01-19 16-01-19 -
Houder van rechten
See clinicaltrials.gov
Geüploaded op
16 januari 2019
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Prostate Cancer Recurrent NCT01512472
Eligibility Prostate Cancer Recurrent NCT01512472
- StudyEvent: Eligibility
Similar models
Eligibility Prostate Cancer Recurrent NCT01512472
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Adenocarcinoma of prostate | Indication Hormone Therapy Intermittent
Item
histologically confirmed adenocarcinoma of the prostate for which intermittent endocrine treatment therapy is indicated
boolean
C0007112 (UMLS CUI [1])
C3146298 (UMLS CUI [2,1])
C0279025 (UMLS CUI [2,2])
C0205267 (UMLS CUI [2,3])
C3146298 (UMLS CUI [2,1])
C0279025 (UMLS CUI [2,2])
C0205267 (UMLS CUI [2,3])
PSA Level Criteria Fulfill
Item
psa level meeting both of these criteria:
boolean
C4086720 (UMLS CUI [1,1])
C0243161 (UMLS CUI [1,2])
C1550543 (UMLS CUI [1,3])
C0243161 (UMLS CUI [1,2])
C1550543 (UMLS CUI [1,3])
PSA Level
Item
psa level of ≥ 5 ng/ml.
boolean
C4086720 (UMLS CUI [1])
Recurrence Post Therapeutic radiology procedure | Recurrence Post Cold Therapy | Prostate specific antigen measurement Quantity
Item
for patients with recurrence after radiotherapy or cryotherapy: patients should have a serum psa (two measurements) to be >2 ng/ml higher than a previously confirmed psa nadir.
boolean
C2825055 (UMLS CUI [1,1])
C0687676 (UMLS CUI [1,2])
C1522449 (UMLS CUI [1,3])
C2825055 (UMLS CUI [2,1])
C0687676 (UMLS CUI [2,2])
C0010412 (UMLS CUI [2,3])
C0201544 (UMLS CUI [3,1])
C1265611 (UMLS CUI [3,2])
C0687676 (UMLS CUI [1,2])
C1522449 (UMLS CUI [1,3])
C2825055 (UMLS CUI [2,1])
C0687676 (UMLS CUI [2,2])
C0010412 (UMLS CUI [2,3])
C0201544 (UMLS CUI [3,1])
C1265611 (UMLS CUI [3,2])
Serum testosterone measurement
Item
screening serum testosterone level above the lower limit of normal range defined as >2.2 ng/ml.
boolean
C0428413 (UMLS CUI [1])
Management Hormonal Prostate carcinoma | Surgical castration
Item
has had previous or is currently under hormonal management of prostate cancer (surgical castration or other hormonal manipulation)
boolean
C0376636 (UMLS CUI [1,1])
C0458083 (UMLS CUI [1,2])
C0600139 (UMLS CUI [1,3])
C0007344 (UMLS CUI [2])
C0458083 (UMLS CUI [1,2])
C0600139 (UMLS CUI [1,3])
C0007344 (UMLS CUI [2])
5-alpha Reductase Inhibitors | Finasteride | Dutasteride
Item
has received therapy with the 5-alpha reductase inhibitors finasteride or dutasteride within 12 weeks and 25 weeks, respectively, prior to screening
boolean
C2936788 (UMLS CUI [1])
C0060389 (UMLS CUI [2])
C0754659 (UMLS CUI [3])
C0060389 (UMLS CUI [2])
C0754659 (UMLS CUI [3])